A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton

Small GTPases

Volumn 6, Issue 4, 2015, Pages 202-211

  Ali, Naveid ^a   Jurczyluk, Julie ^a   Shay, Gemma ^b,e   Tnimov, Zakir ^c   Alexandrov, Kirill ^c   Munoz, Marcia A ^a   Skinner, Oliver P ^a   Pavlos, Nathan J ^d   Rogers, Michael J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bisphosphonate; Geranylgeranyl transferase; Macrophage; Prenylation; Rab

Indexed keywords

CD11B ANTIGEN; GUANOSINE TRIPHOSPHATASE; PROTEOME; RAB PROTEIN; RAB11 PROTEIN; RAB7 PROTEIN; RAC1 PROTEIN; RHO FACTOR; STREPTAVIDIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DISEASE; BONE MARROW CELL; CELL LINE; CELL LYSATE; CONTROLLED STUDY; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; J774 CELL LINE; MASS SPECTROMETRY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PERITONEUM MACROPHAGE; PRENYLATION; PROTEIN ANALYSIS; PROTEIN BLOTTING; SKELETON; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; METABOLISM; PROTEIN PRENYLATION;

ANIMALS; CELL LINE; DIPHOSPHONATES; IMIDAZOLES; MACROPHAGES, PERITONEAL; MICE; PROTEIN PRENYLATION; RAB GTP-BINDING PROTEINS;

EID: 84961564487     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.1080/21541248.2015.1085485     Document Type: Article

References (42)

1. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-42; PMID:11160603
2. Rondeau JM, Bitsch F, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. J Med Chem 2006; 1:267-73
3. Kavanagh K, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RGG, Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as anti-osteoporosis drugs: crystal structure and inhibition of farnesyl pyrophosphate synthase. Proc Natl Acad Sci 2006; 103 7829-34; PMID:16684881; http://dx.doi.org/10.1073/pnas.0601643103
4. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-9; PMID:9556058; http://dx.doi.org/10.1359/jbmr.1998.13.4.581
5. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49:34-41; PMID:21111853; http://dx.doi.org/10.1016/j.bone.2010.11.008
6. McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci 2006; 63:255-67; PMID:16378247; http://dx.doi.org/10.1007/s00018-005-5298-6
7. Coxon FP, Helfrich MH, van ’t Hof RJ, Sebti SM, Ralston SH, Hamilton AD, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15:1467-76; PMID:10934645; http://dx.doi.org/10.1359/jbmr.2000.15.8.1467
8. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42 and Rho GTPases. J Bone Miner Res 2006; 21 684-94; PMID:16734383; http://dx.doi.org/10.1359/jbmr.060118
9. Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2011; 2:117-30; PMID:21776413; http://dx.doi.org/10.4161/sgtp.2.3.16453
10. Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012; 48:187-95; PMID:22100904; http://dx.doi.org/10.1016/j.ejca.2011.10.021
11. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013; 18:353-61; PMID:23404816; http://dx.doi.org/10.1634/theoncologist.2012-0261
12. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95:1174-81; PMID:20080842; http://dx.doi.org/10.1210/jc.2009-0852
13. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:1989-99; PMID:21131037; http://dx.doi.org/10.1016/S0140-6736(10)62051-X
14. Gnant M, Mlineritsch B, Schippinger W, Luschin- Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-91; PMID:19213681; http://dx.doi.org/10.1056/NEJMoa0806285
15. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365:1396-405; PMID:21995387; http://dx.doi.org/10.1056/NEJMoa1105195
16. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZOFAST study): final 60-month results. Annals Oncol 2013; 24:398-405; http://dx.doi.org/10.1093/annonc/mds277
17. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endo Metab 2011; 96:1006-14; http://dx.doi.org/10.1210/jc.2010-2730
18. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 2007; 357:1799-809; PMID:17878149; http://dx.doi.org/10.1056/NEJMoa074941
19. Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, et al. Real time intravital imaging establishes tumourassociated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discovery 2015; 5:35-42; PMID:25312016; http://dx.doi.org/10.1158/2159-8290.CD-14-0621
20. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006; 69(5):1624-32; PMID:16501031; http://dx.doi.org/10.1124/mol.105.020776
21. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009; 144:245-50; PMID:19016713; http://dx.doi.org/10.1111/j.1365-2141.2008.07435.x
22. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010; 25:606-16; PMID:20422624; http://dx.doi.org/10.1359/jbmr.091009
23. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages. Curr Pharm Des 2010; 16:2950-60; PMID:20722616; http://dx.doi.org/10.2174/138161210793563635
24. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12:6222s-30s; PMID:17062705; http://dx.doi.org/10.1158/1078-0432.CCR-06-0843
25. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008; 42:848-60; PMID:18325866; http://dx.doi.org/10.1016/j.bone.2007.12.225
26. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001; 44:2201-10; PMID:11592386; http://dx.doi.org/10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E
27. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005; 37:349-58; PMID:16006204; http://dx.doi.org/10.1016/j.bone.2005.04.021
28. Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 2005; 7:297-300; PMID:15837619; http://dx.doi.org/10.1016/j.ccr.2005.04.005
29. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42:1228-36; PMID:12412821; http://dx.doi.org/10.1177/009127002762491316
30. Rhim SY, Park JH, Park YS, Lee MH, Kim DS, Shaw LM, Yang SC, Kang JS. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. Clinical Therapeutics 2009; 31:1037-45; PMID:19539104; http://dx.doi.org/10.1016/j.clinthera.2009.05.001
31. Nguyen UT, Guo Z, Delon C, Wu Y, Deraeve C, Franzel B, Bon RS, Blankenfeldt W, Goody RS, Waldmann H, et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat Chem Biol 2009; 5:227-35; PMID:19219049; http://dx.doi.org/10.1038/nchembio.149
32. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure- activity relationships in J774 macrophages. J Bone Miner Res 1998; 13:1668-78; PMID:9797474; http://dx.doi.org/10.1359/jbmr.1998.13.11.1668
33. Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003; 18:204-12; PMID:12568397; http://dx.doi.org/10.1359/jbmr.2003.18.2.204
34. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55:210-24; http://dx.doi.org/10.1002/ddr.10071
35. Gutierrez MG. Functional role(s) of phagosomal Rab GTPases. Small GTPases 2013; 4:148-58; PMID:24088602; http://dx.doi.org/10.4161/sgtp.25604
36. Kohnke M, Delon C, Hastie ML, Nguyen UT, Wu YW, Waldmann H, Goody RS, Gorman JJ, Alexandrov K. Rab GTPase prenylation hierarchy and its potential role in choroideremia disease. PloS One 2013; 8:e81758; PMID:24358126; http://dx.doi.org/10.1371/journal.pone.0081758
37. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011; 103:232-40; PMID:21189409; http://dx.doi.org/10.1093/jnci/djq516
38. Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res 2013; 19:3176-88; PMID:23616636; http://dx.doi.org/10.1158/1078-0432.CCR-13-0042
39. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1:376-86; PMID:12118079; http://dx.doi.org/10.1074/mcpM200025-MCP200
40. Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 2003; 75:663-70; PMID:12585499; http://dx.doi.org/10.1021/ac026117i
41. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nature Protocols 2006; 1:2856-60; PMID:17406544; http://dx.doi.org/10.1038/nprot.2006.468
42. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011; 10:1794-805; PMID:21254760; http://dx.doi.org/10.1021/pr101065j